| Identification | Back Directory | [Name]
Pyrazolo[1,5-a]pyridine-3-carbonitrile, 6-[[(2R)-2-hydroxy-2-methyl-3-butyn-1-yl]oxy]-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]- | [CAS]
2546117-79-5 | [Synonyms]
Pyrazolo[1,5-a]pyridine-3-carbonitrile, 6-[[(2R)-2-hydroxy-2-methyl-3-butyn-1-yl]oxy]-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]- | [Molecular Formula]
C30H29N7O3 | [MOL File]
2546117-79-5.mol | [Molecular Weight]
535.6 |
| Hazard Information | Back Directory | [Description]
Resencatinib is a tyrosine kinase inhibitor with potential as an antineoplastic agent. | [Uses]
Resencatinib is a potent tyrosine kinase inhibitor with antineoplastic activity[1]. Resencatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | [References]
[1] WHO Drug Information-World Health Organization (WHO). |
|
|